Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial

S. J. Antonia, José A. López-Martin, Johanna C. Bendell, Patrick A. Ott, Matthew Taylor, Joseph Paul Eder, Dirk Jäger, M. Catherine Pietanza, Dung Le, Michael A. Morse, Paolo Antonio Ascierto, L. Horn, Asim Amin, Rathi N. Pillai, Jeffrey Evans, Ian Chau, P. Bono, Akin Atmaca, Padmanee Sharma, Christopher T. HarbisonChen Sheng Lin, Olaf Christensen, E. Calvo

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences